Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab vs platinum-based chemotherapy in first-line PD-L1 positive advanced NSCLC
2016-004407-31Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cemiplimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Overall survival and Progression-free survival. Started May 2017; status: completed.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-004407-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004407-31.